Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins

  1. P. J. Moos,
  2. K. Edes, and
  3. F. A. Fitzpatrick*
  1. Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112-5550
  1. Communicated by Raymond L. White, University of Utah, Salt Lake City, UT (received for review March 9, 2000)

Abstract

The electrophilic eicosanoids prostaglandins A1 or A2 impaired p53-dependent transcription of endogenous genes and exogenous p53-luciferase reporter plasmids in RKO and HCT 116 colon cancer cells. Cellular accumulation of genetically wild-type, but transcriptionally silent p53 varied as a function of exposure time and concentration of prostaglandins A1 and A2. Prostaglandins A1 and A2 induced a conformational change in wild-type p53 that corresponded with its inactivation and its aberrant redistribution from the cytosol to the nucleus. Derangement of its transcriptional activity manifested as inhibition of p53-mediated apoptosis by etoposide, a representative antineoplastic agent. We conclude that electrophilic eicosanoids impair the role of wild-type p53 as a guardian of genomic integrity by a process distinct from somatic mutation or viral oncoprotein binding. This process may pertain to malignant and premalignant conditions, such as colon carcinoma and adenoma, which often harbor a genetically wild-type, but inactive form of p53 tumor suppressor.

Footnotes

  • * To whom reprint requests should be addressed. E-mail: frank.fitzpatrick{at}hci.utah.edu.

  • Article published online before print: Proc. Natl. Acad. Sci. USA, 10.1073/pnas.160241897.

  • Article and publication date are at www.pnas.org/cgi/doi/10.1073/pnas.160241897

  • Abbreviations:
    p21,
    p21Waf−1/Cip−1;
    PG,
    prostaglandin
« Previous | Next Article »Table of Contents